Search results

Filter

Filetype

Your search for "*" yielded 130775 hits

Spin-off companies

Lead Biologics Lead Biologics was founded in 2022 by Thoas Fioretos, Carl Sandén and Marcus Järås (Lund University), Kjell Sjöström (Innovagen) and Niklas Landberg (SUS). The company combines state-of-the-art technologies with unique patient cohorts to identify multiple novel therapeutic targets in leukemias and solid tumors. The aim is to develop a first-in-class treatment against SLAMF6. A major

https://www.createhealth.lth.se/impact/spin-companies - 2026-11-15

CanFaster

The Translational Cancer Faster Forward doctoral/postdoctoral programmes (2018-2025). The CanFaster programme is supported by the European Union’s Marie Skłodowska-Curie COFUND programme (Horizon 2020 framework) based on the "Mobility across borders" philosophy.  The CanFaster programme has attracted international PhD and Postdoc fellows (ER) with an interest in applied medical research in oncolog

https://www.createhealth.lth.se/impact/canfaster - 2026-11-15

CanFaster Publications

The links below open on the respective publication website. In vivo dendritic cell reprogramming for cancer immunotherapy. Authors: Ascic, E., Catena, X., et al. Publication: Science 386, 6719 Year: 2024 Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab. Authors: Meng, P., Dalal, H., Chen, Y., Brueffer, C., Gladchuk, S., Alcaide, M.,

https://www.createhealth.lth.se/impact/canfaster/canfaster-publications - 2026-11-15

Inducing anti-tumor immunity with in-situ direct reprograming of cancer cells to cDC1s

Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient antigen presentation mediated by MHC downregulation and exclusion of functional antigen-presenting cells (APCs) from the tumor microenvironment (TME) are critical evas

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/inducing-anti-tumor-immunity-situ-direct-reprograming-cancer-cells-cdc1s - 2026-11-15

Next generation immuno-oncological targets for cancer therapy

Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/next-generation-immuno-oncological-targets-cancer-therapy - 2026-11-15

Subtype-dependent biomarkers for systemic therapy in bladder cancer

Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health outcomes [ 1 ]. To patients with superficial cancer limited to the mucosa of the urinary bladder, the prognosis is good, but once the tumor has grown into the muscle-l

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/subtype-dependent-biomarkers-systemic-therapy-bladder-cancer - 2026-11-15

About

CREATE Health, inaugurated in 2006 with a focus on precision medicine, is a strategic centre for translational research focusing on the early diagnosis and prognosis of cancer, as well as the development of novel treatment strategies. Our vision: To accelerate translation of breakthrough therapies and diagnostics into clinical practice, improving outcomes for today´s cancer patients while building

https://www.createhealth.lth.se/about - 2026-11-15

Research

Our research accompanies the entire patient journey, from initial diagnosis through treatment and companion diagnostics to quality-of-life enhancement during and after cancer. We deliver translational solutions that start from specific clinical needs identified by our clinical partners, leveraging novel technological approaches to accelerate implementation into the clinic with dramatically reduced

https://www.createhealth.lth.se/research - 2026-11-15

Research projects

Lund University research projects Currently at Lund Univeristy, ten research projects are driven by ten Principle Investigators from the Faculty of Engineering (LTH) and the Faculty of Medicine. The common goal of all of them is to deepen knowledge and fast forward innovations in cancer diagnostics and treatment. Molecular characterisation of breast cancer: biomarkers of risk, prognosis and treatm

https://www.createhealth.lth.se/research/research-projects - 2026-11-15

Funding

In 2025, CREATE Health Translational Cancer Center received a donation from the Mrs Berta Kamprad’s Cancer Foundation of 420 million SEK. This is the single largest donation to Lund University, since its founding in 1666. The funds are distributed over a five-year period and dedicated to translational cancer research within the L2CancerBridge programme. Other previous and current funding for the C

https://www.createhealth.lth.se/about/funding - 2026-11-15

L2CancerBridge Programme - Collaborative Excellence

L2CancerBridge is a groundbreaking collaborative cancer research programme that bridges two of Europe's leading research institutions: CREATE Health at Lund University, Sweden, and the Swiss Cancer Centre at EPFL in Lausanne, Switzerland. The L2CancerBridge programme exemplifies how international partnerships can accelerate cancer research breakthroughs. By combining the expertise and resources of

https://www.createhealth.lth.se/research/l2cancerbridge-programme-collaborative-excellence - 2026-11-15

Technologies

Antibody Initiative Advances in antibody engineering have revolutionised cancer therapy, and biological drugs now constitute a cornerstone of frontline treatment across most cancer subtypes. We drive continued innovation and clinical success by continuously enhancing local capabilities in Lund to develop tailored molecules for targeted cancer treatment- specific antigens, immune checkpoints, or as

https://www.createhealth.lth.se/research/technologies - 2026-11-15

Infrastructure

Computational Chemistry promotes the usage of X-ray and neutron scattering techniques and provides the researchers at LU with a facility where it is possible to measure and simulate macromolecules in solution and serve as an entry environment to the large scale infrastructures. Computational Cehmistry also promotes software for classical molecular simulations, multireference quantum chemistry calc

https://www.compchem.lu.se/infrastructure - 2026-11-15

Software

Faunus Faunus is a free, object oriented library for classical molecular simulations written in C++/Python. Besides handling macromolecular solutions in various ensembles such as NVT, μVT, NPT, Faunus also covers more excotic topics such as proton fluctuations, arbitrary parallel tempering and hyperspherical geometry. More information on the Faunus website Molcas MOLCAS  is a quantum chemistry sof

https://www.compchem.lu.se/infrastructure/software - 2026-11-15

BioSAXS Instrument

In 2021 Infrastructure Call at Lund University, we were gratefully approved funding from LU Central, the Science Faculty, and the Faculty of Engineering for purchasing a Solution X-ray Scattering Instrument for Life Science and Soft Matter, short-name the BioSAXS. Our vision is to promote the usage of X-ray and neutron scattering techniques and provide the researchers at LU with a facility where i

https://www.compchem.lu.se/infrastructure/biosaxs-instrument - 2026-11-15